Cited by 5,761Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Open access

Sandler, Alan, Gray, Robert, Perry, Michael C., Brahmer, Julie, Schiller, Joan H., Dowlati, Afshin, Lilenbaum, Rogerio, Johnson, David H.·2006·New England Journal of Medicine

DOI 10.1056/nejmoa061884

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival. RESULTS: The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa061884

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citation
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,985

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 4

Brown LF, 1993, Cancer Res, 53, 4727
Kabbinavar FF, 1995, Proc Am Assoc Cancer Res, 36, 488
Borgstrom P, 1999, Anticancer Res, 19, 4203
Miller KD, 2005, Breast Cancer Res Treat, 94, S6

Sorted by citations

Items 501–600 of 1,018

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care
Bose, D., Meric‐Bernstam, F., Hofstetter, W. L., Reardon, D. A., Flaherty, K. T., & Ellis, L. M. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70341-9 · Cited by 138
LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma
Teng, F., Zhang, J., Chang, Q., Wu, X., Tang, W., Wang, J., Feng, J.-F., Zhang, Z., & Hu, Z. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01739-z · Cited by 135
Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors
Cabebe, E. C., & Wakelee, H. A. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0022-4 · Cited by 134
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
Novello, S., Scagliotti, G. V., Rosell, R., Socinski, M. A., Brahmer, J. R., Atkins, J., Pallarés, C., Burgess, R., Tye, L., Selaru, P., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605346 · Cited by 134
Self-citation
Targeted inhibition of VEGF receptor 2: an update on ramucirumab
Clarke, J. M., & Hurwitz, H. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.810717 · Cited by 136
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy
Felip, E., Gridelli, C., Baas, P., Rosell, R., & Stahel, R. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr150 · Cited by 134
Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer
Hanrahan, E. O., Lin, H. Y., Kim, E. S., Yan, S., Du, D. Z., McKee, K. S., Tran, H. T., Lee, J. J., Ryan, A. J., Langmuir, P. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4279 · Cited by 134
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival
Babu, R., Komisarow, J. M., Agarwal, V. J., Rahimpour, S., Iyer, A., Britt, D., Karikari, I. O., Grossi, P. M., Thomas, S. M., Friedman, A. H., et al. (2015) · Journal of neurosurgery · doi:10.3171/2015.4.jns142200 · Cited by 132
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
Reardon, D. A., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., McLendon, R. E., Herndon, J. E., Bulusu, A., Threatt, S., Friedman, A. H., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0722-2 · Cited by 132
Side effects of anti-angiogenic drugs
Elice, F., & Rodeghiero, F. (2012) · Thrombosis Research · doi:10.1016/s0049-3848(12)70016-6 · Cited by 133
Evolution of the EU Biosimilar Framework: Past and Future
Wolff‐Holz, E., Tiitso, K., Vleminckx, C., & Weise, M. (2019) · BioDrugs · doi:10.1007/s40259-019-00377-y · Cited by 133
Vessel co-option and resistance to anti-angiogenic therapy
Kuczynski, E. A., & Reynolds, A. R. (2019) · Angiogenesis · doi:10.1007/s10456-019-09698-6 · Cited by 138
Nedaplatin: a cisplatin derivative in cancer chemotherapy
Shimada, M., Kigawa, J., & Itamochi (2013) · Cancer Management and Research · doi:10.2147/cmar.s35785 · Cited by 133
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
Li, J. (2009) · Frontiers in bioscience · doi:10.2741/3438 · Cited by 134
Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line
Leighl, N. B. (2012) · Current Oncology · doi:10.3747/co.19.1114 · Cited by 134
Bevacizumab for the Treatment of Recurrent Glioblastoma
Chamberlain, M. C. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7232 · Cited by 136
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
Hsu, C., Yang, T.-S., Hsu, C., Toh, H. C., Epstein, R. J., Hsiao, L.-T., Chen, P.-J., Lin, Z.-Z., Chao, T.-Y., & Cheng, A.-L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605580 · Cited by 132
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Ellis, P. M., Shepherd, F. A., Millward, M. J., Perrone, F., Seymour, L., Liu, G., Sun, S. B., Cho, B. C., Morabito, A., Leighl, N. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70472-3 · Cited by 135
Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411
Crane, C. H., Winter, K. A., Regine, W. F., Safran, H. P., Rich, T. A., Curran, W. J., Wolff, R. A., & Willett, C. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8529 · Cited by 132
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30561-7 · Cited by 133
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 135
O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Hejleh, T. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.008 · Cited by 134
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications
Eskander, R. N., & Tewari, K. S. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.029 · Cited by 131
Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
Boige, V., Malka, D., Bourredjem, A., Dromain, C., Baey, C., Jacques, N., Pignon, J., Vimond, N., Bouvet-Forteau, N., de Baère, T., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0465 · Cited by 131
Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens
Khayyata, S. H., Yun, S. S., Pasha, T. L., Jian, B., McGrath, C. M., Yu, G. H., Gupta, P. K., & Baloch, Z. W. (2009) · Diagnostic Cytopathology · doi:10.1002/dc.20975 · Cited by 131
Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition
Casás‐Selves, M., Kim, J., Zhang, Z., Helfrich, B. A., Gao, D., Porter, C. C., Scarborough, H. A., Bunn, P. A., Chan, D. C. F., Tan, A. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2848 · Cited by 132
Chemotherapy remains an essential element of personalized care for persons with lung cancers
Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 136
Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs
Otterson, G. A., Villalona-Calero, M. A., Sharma, S., Kris, M. G., Imondi, A. R., Gerber, M. C., White, D. A., Ratain, M. J., Schiller, J. H., Sandler, A. B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1096 · Cited by 130
Self-citation
Lung Cancer Screening With Low-Dose Computed Tomography: Costs, National Expenditures, and Cost-Effectiveness
Goulart, B. H. L., Bensink, M. E., Mummy, D. G., & Ramsey, S. D. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0023 · Cited by 128
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 134
Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer
Dønnem, T., Andersen, S., Al-Shibli, K. I., Al‐Saad, S., Busund, L., & Bremnes, R. M. (2010) · Cancer · doi:10.1002/cncr.25551 · Cited by 131
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 133
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
Manegold, C., van Zandwijk, N., Szczęsna, A., Zatloukal, P., Au, J. S. K., Błasińska-Morawiec, M., Serwatowski, P., Krzakowski, M. J., Jassem, J., Tan, E. H., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr030 · Cited by 128
Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer
Zhang, D., Sun, B., Zhao, X., Ma, Y., Ji, R., Gu, Q., Dong, X., Li, J., Liu, F., Jia, X., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-207 · Cited by 128
Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
Hariharan, S., Gustafson, D. L., Holden, S. N., McConkey, D. J., Davis, D. W., Morrow, M., Basche, M., Gore, L., Zang, C., O’Bryant, C. L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm140 · Cited by 130
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
McKeage, M. J., von Pawel, J., Reck, M., Jameson, M. B., Rosenthal, M. A., Sullivan, R., Gibbs, D. D., Mainwaring, P. N., Serke, M. H., Lafitte, J. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604808 · Cited by 127
Role of epidermal growth factor receptor in lung cancer and targeted therapies.
Liu, T., Jin, X., Wang, Y., & Wang, K. (2017) · Europe PMC (PubMed Central) · Cited by 131
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126
Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
Scagliotti, G. V., Novello, S., Schiller, J. H., Hirsh, V., Sequist, L. V. D., Soria, J., von Pawel, J., Schwartz, B. E., von Roemeling, R., & Sandler, A. B. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.003 · Cited by 126
Self-citation
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma
Pérez, D. G., Suman, V. J., Fitch, T. R., AMATRUDA, T. T., Morton, R. F., Jilani, S. Z., Constantinou, C. L., Egner, J. R., Kottschade, L. A., & Markovic, S. N. (2008) · Cancer · doi:10.1002/cncr.23987 · Cited by 124
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A. F., Bonifati, L. G., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.4609 · Cited by 131
The Antifungal Drug Itraconazole Inhibits Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, Trafficking, and Signaling in Endothelial Cells
Nacev, B. A., Grassi, P., Dell, A., Haslam, S. M., & Liu, J. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.278754 · Cited by 130
Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model
Ito, A., Ishida, T., Yano, H., Inagaki, A., Suzuki, S., Sato, F., Takino, H., Mori, F., Ri, M., Kusumoto, S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0632-0 · Cited by 133
Mouse models for studying angiogenesis and lymphangiogenesis in cancer
Eklund, L., Bry, M., & Alitalo, K. K. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.007 · Cited by 133
A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
Hensing, T. A., Chawla, A., Batra, R., & Salgia, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8778-4_5 · Cited by 127
Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma
Moriya, Y., Nohata, N., Kinoshita, T., Mutallip, M., Okamoto, T., Yoshida, S., Suzuki, M., Yoshino, I., & Seki, N. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2011.126 · Cited by 123
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
Tocchetti, C. G., Dessalvi, C. C., Lisi, D. D., Femminò, S., Madonna, R., Mele, D., Monte, I. P., Novo, G., Penna, C. R. R., Pepe, A., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6930 · Cited by 132
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With AdvancedEGFR-Mutant Non–Small Cell Lung Cancer
Stinchcombe, T. E., Janne, P. A., Wang, X., Bertino, E. M., Weiss, J. M., Bazhenova, L. A., Gu, L., Lau, C. J., Paweletz, C. P., Jaslowski, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1847 · Cited by 126
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis
Baggstrom, M. Q., Stinchcombe, T. E., Fried, D. B., Poole, C., Hensing, T. A., & Socinski, M. A. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31814617a2 · Cited by 124
Proinflammatory Role of Vascular Endothelial Growth Factor in the Pathogenesis of Rheumatoid Arthritis: Prospects for Therapeutic Intervention
Yoo, S., Kwok, S., & Kim, W. (2008) · Mediators of Inflammation · doi:10.1155/2008/129873 · Cited by 125
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
Dean, E. J., Middleton, M. R., Pwint, T. P., Swaisland, H., Carmichael, J., Goodege, P., & Ranson, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.555 · Cited by 125
Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation
Oguro, Y., Miyamoto, N., Okada, K., Takagi, T., Iwata, H., Awazu, Y., Miki, H., Hori, A., Kamiyama, K., & Imamura, S. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.017 · Cited by 126
Ultrasound induced cancer immunotherapy
Unga, J., & Hashida, M. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.03.004 · Cited by 125
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Soria, J., Massard, C., & Chevalier, T. L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq204 · Cited by 123
Targeted therapy for non-small-cell lung cancer: past, present and future
Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 123
VEGF-A Expression Correlates with TP53 Mutations in Non–Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy
Schwaederle, M. C., Lazar, V., Validire, P., Hansson, J., Lacroix, L., Soria, J., Yudi Pawitan, Y., & Kurzrock, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2305 · Cited by 123
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Michalopoulou, P., Bastas, A., Marosis, K., Stathopoulos, J., Provata, A., Yiamboudakis, P., Veldekis, D., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq234 · Cited by 123
Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers
Chaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829923ec · Cited by 122
Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study
Zabaleta, V., Ponchel, G., Salman, H. H., Agüeros, M., Vauthier, C., & Irache, J. M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.04.001 · Cited by 122
Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Non–Small Cell Lung Cancer
Sharma, D. B. (2012) · JAMA · doi:10.1001/jama.2012.454 · Cited by 122
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
Castria, T. B. D., da Silva, E. M., de Góis, A. F. T., & Riera, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009256.pub2 · Cited by 122
Prognostic Impact of Cancer-Associated Stromal Cells in Patients With Stage I Lung Adenocarcinoma
Ito, M., Ishii, G., Nagai, K., Maeda, R., Nakano, Y., & Ochiai, A. (2012) · CHEST Journal · doi:10.1378/chest.11-2458 · Cited by 123
The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
Ye, W. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.03.015 · Cited by 124
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
Olaussen, K. A., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw321 · Cited by 124
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J. A., Yeh, B. M., Lake, D. E., Dang, C. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0141 · Cited by 120
Understanding and managing the possible adverse effects associated with bevacizumab
Shord, S. S., Bressler, L. R., Tierney, L. A., Cuéllar, S., & George, A. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080455 · Cited by 122
Biomaterial‐Based Implantable Devices for Cancer Therapy
Chew, S. A., & Danti, S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201600766 · Cited by 121
Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003
Cipriano, L. E., Romanus, D., Earle, C. C., Neville, B. A., Halpern, E. F., Gazelle, G. S., & McMahon, P. M. (2011) · Value in Health · doi:10.1016/j.jval.2010.10.006 · Cited by 121
Revisiting the seed and soil in cancer metastasis
Mendoza, M., & Khanna, C. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.01.015 · Cited by 126
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kamath, A. V., Smykla, R. A., Kramer, R. A., & Vite, G. D. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0724-8 · Cited by 121
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 121
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Chi, A. S., Sorensen, A. G., Jain, R. K., & Batchelor, T. T. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0272 · Cited by 121
Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies
Shojaei, F., & Ferrara, N. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.09.001 · Cited by 119
Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?
Vaklavas, C., Lenihan, D. J., Kurzrock, R., & Tsimberidou, A. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0252 · Cited by 119
Anti-angiogenesis target therapy for advanced osteosarcoma
Xie, L., Ji, T., & Guo, W. (2017) · Oncology Reports · doi:10.3892/or.2017.5735 · Cited by 119
Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma
Qu, Y., Emoto, K., Eguchi, T., Aly, R. G. M., Zheng, H., Chaft, J. E., Tan, K. S., Jones, D. R., Kris, M. G., Adusumilli, P. S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.017 · Cited by 122
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 120
Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021) · Cancers · doi:10.3390/cancers13174444 · Cited by 128
Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer
Fujioka, N., Nguyen, J., Chen, C., Li, Y., Pasrija, T., Niehans, G. A., Johnson, K., Gupta, V., Kratzke, R. A., & Gupta, K. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318232b35a · Cited by 119
Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group
Laurie, S. A., Gauthier, I. C., Arnold, A., Shepherd, F. A., Ellis, P. M., Chen, E. X., Goss, G. D., Powers, J., Walsh, W., Tu, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4741 · Cited by 119
Sunitinib in solid tumors
Gan, H. K., Šeruga, B., & Knox, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902980171 · Cited by 119
Gene Therapy and Targeted Toxins for Glioma
King, G. D., Curtin, J. F., Candolfi, M., Kroeger, K. M., Lowenstein, P. R., & Castro, M. G. (2005) · Current Gene Therapy · doi:10.2174/156652305774964631 · Cited by 118
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer
Connolly, G. C., Dalal, M. R., Lin, J., & Khorana, A. A. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.007 · Cited by 118
Vascular endothelial growth factor in the management of hepatocellular carcinoma
Kaseb, A. O., Hanbali, A. S., Cotant, M. B., Hassan, M. M., WOLLNER, I. S., & Philip, P. A. (2009) · Cancer · doi:10.1002/cncr.24537 · Cited by 117
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Argiris, A. E., Karamouzis, M. V., Gooding, W. E., Branstetter, B. F., Zhong, S., Raez, L. E., Savvides, P. S., & Romkes, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3591 · Cited by 117
Elevated Serum Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios Could be Useful in Lung Cancer Diagnosis
Kemal, Y., Yücel, İ., Ekiz, K., Demirağ, G., Yılmaz, B., Teker, F., & Ozdemir, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.6.2651 · Cited by 117
Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status
Goss, G. D., Ferry, D. R., Wierzbicki, R. F., Laurie, S. A., Thompson, J., Biesma, B., Hirsch, F. R., Varella‐Garcia, M., Duffield, E. L., Ataman, Ö., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.4408 · Cited by 117
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Lazzari, C., Karachaliou, N., Bulotta, A., Viganò, M., Mirabile, A., Brioschi, E., Santarpía, M., Gianni, L., Rosell, R., & Gregorc, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918762094 · Cited by 123
Secreted Frizzle-Related Protein 2 Stimulates Angiogenesis via a Calcineurin/NFAT Signaling Pathway
Courtwright, A., Siamakpour‐Reihani, S., Arbiser, J. L., Banet, N., Hilliard, E., Fried, L. E., Livasy, C., Ketelsen, D., Nepal, D. B., Perou, C. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3402 · Cited by 117
Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network
Hainsworth, J. D., Spigel, D. R., Farley, C. P., Thompson, D. S., Shipley, D. L., & Greco, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3047 · Cited by 117
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab
Finn, R. S., & Zhu, A. X. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.6 · Cited by 117
Promising systemic immunotherapies in head and neck squamous cell carcinoma
Gildener‐Leapman, N., Ferris, R. L., & Bauman, J. E. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.009 · Cited by 116
Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
Shen, H., Zhu, F., Liu, J., Xu, T., Pei, D., Wang, R., Qian, Y., Li, Q., Wang, L., Shi, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103305 · Cited by 116
Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer
Reynolds, A. R. (2010) · Dose-Response · doi:10.2203/dose-response.09-049.reynolds · Cited by 119
Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice
Gingis‐Velitski, S., Loven, D., Benayoun, L., Munster, M., Bril, R., Voloshin, T., Alishekevitz, D., Bertolini, F., & Shaked, Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0629 · Cited by 111

Authors: Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H.
Affiliations: Vanderbilt University (US)
Dana-Farber Cancer Institute (US)
University of Missouri (US)
Johns Hopkins University (US)
University of Wisconsin–Madison (US)
University Hospitals of Cleveland (US)
ORCID: Sandler, Alan
Gray, Robert
Brahmer, Julie
Schiller, Joan H.
Dowlati, Afshin
Johnson, David H.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-12-14
Volume: 355
Issue: 24
Pages: 2542-2550
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa061884
OpenAlex: W2145835533
Cited by: 5,761
References: 24
Citations by year: 2026: 49 · 2025: 71 · 2024: 112 · 2023: 135 · 2022: 177 · 2021: 183 · 2020: 180 · 2019: 227 · 2018: 257 · 2017: 278 · 2016: 321 · 2015: 389 · 2014: 400 · 2013: 461 · 2012: 513
FWCI: 299.17
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (U10CA066636, CA-23318, CA49957, U10CA016116, CA66636, U10CA012046, U10CA014548, CA-16116, CA14548, U10CA031946, CA21076, U10CA049957, U10CA021076, U10CA023318, U10CA021115, CA 21115, CA-31946, CA12046)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, bevacizumab, paclitaxel, carboplatin, combination chemotherapy, vascular endothelial growth factor inhibition, overall survival, progression-free survival, pulmonary hemorrhage
MeSH terms: Bevacizumab, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Carboplatin, Paclitaxel, Disease-Free Survival, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks